Nautilus Biotechnology (NAUT) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nautilus Biotechnology (NAUT) has outperformed Upstream Bio (UPB) over the past year, gaining 126.3% versus a loss of 75.3%. Upstream Bio is the larger company by market cap ($243.7 million vs $235.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAUT | UPB |
|---|---|---|
| Share price | $1.85 | $4.45 |
| Market cap | $235.42M | $243.73M |
| 1-day change | -5.61% | -3.47% |
| YTD return | +0.51% | -83.02% |
| 1-year return | +126.33% | -75.31% |
| 5-year return | -65.67% | — |
| EPS (TTM) | $-0.45 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.31 | $33.68 |
| 52-week low | $0.82 | $4.39 |
| Distance from 52-week high | -57.08% | -86.79% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +107.03% | +599.78% |
| Average volume | 2.59M | 610.08K |
| Shares outstanding | 127.26M | 54.77M |
| Employees | 127 | 75 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NAUT has outperformed UPB by 201.6 percentage points over the past year.
- The two companies sit in different sectors: Nautilus Biotechnology in Industrials and Upstream Bio in Health Care.
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 127 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
NAUT vs UPB FAQ
Which is bigger, Nautilus Biotechnology or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $243.73M compared with $235.42M for Nautilus Biotechnology (NAUT).
Which stock has performed better over the past year, NAUT or UPB?
NAUT returned +126.33% over the past 12 months, compared with -75.31% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Nautilus Biotechnology and Upstream Bio in the same industry?
No. Nautilus Biotechnology is in the Industrials sector, while Upstream Bio is in Health Care.